Chronic active antibody-mediated rejection
Conditions
Interventions
Plasma exchange/IVIg + rituximab:Patients were successfully screened with intravenous rituximab (100mg/m2), 4 plasmapheresis/IVIg sessions were started 3 days later, with an interval of one day betwee
Plasma exchange/IVIg + rituximab + tetaercept:Patients were successfully screened with intravenous infusion of rituximab (100mg/m2), 4 plasmapheresis/IVIg sessions were started 3 days later, with an i
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Signed, dated informed consent; (2) Promise to comply with the research procedures and cooperate with the implementation of the whole process of research; (3) Patients aged between 18 and 60 years after kidney transplantation; (4) Positive dnDSA of patients after kidney transplantation; (5) Transplanted kidney biopsy diagnosis of caAMR.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating female patients; (2) the patient has any form of substance abuse, mental illness, or any condition that, in the opinion of the investigators, may interfere with the patient's understanding of the study requirements; (3) Patients who received another investigational drug within 30 days prior to enrollment; (4) Those who have contraindications to the use of mTORi, TAC, CsA and hormones; (5) Active peptic ulcer; (6) Patients with severe cardiopulmonary diseases; (7) Patients with active liver disease; (8) Patients with prior malignant tumors (except for successfully treated localized non-melanocytic skin cancer); (9) Patients who are unable to undergo routine study visits or follow-up, or patients who are followed up in non-certified laboratories.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dnDSA;absolute number of blood lymphocytes;urinary albumintocreatinine ratio;kidney function;Cytomegalovirus DNA load;BK virus DNA load;tacrolimus trough blood concentration;panel reactive antibody;HLA antibody;protocol biopsy;dd-cfDNA;adverse event;high resolution HLA matching of donor and recipient; | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical examination; | — |
Countries
China
Contacts
Public ContactXiaoming Ding
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed